Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $14.32, down -7.07% from its previous closing price of $15.41. In other words, the price has decreased by -$7.07 from its previous closing price. On the day, 3.55 million shares were traded.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.97 and its Current Ratio is at 4.15. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.
Mizuho Upgraded its Neutral to Buy on January 03, 2024, whereas the target price for the stock was revised from $4 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 02 ’25 when Matsuda Masaru sold 5,030 shares for $15.20 per share. The transaction valued at 76,453 led to the insider holds 204,399 shares of the business.
Watanabe Todd Franklin sold 11,448 shares of ARQT for $173,917 on May 02 ’25. The insider now owns 913,795 shares after completing the transaction at $15.19 per share. On May 02 ’25, another insider, Burnett Patrick, who serves as the insider of the company, sold 2,597 shares for $15.19 each. As a result, the insider received 39,442 and left with 119,339 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.68 while its Price-to-Book (P/B) ratio in mrq is 10.71.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $17.75, while it has fallen to a 52-week low of $6.99. The 50-Day Moving Average of the stock is -2.63%, while the 200-Day Moving Average is calculated to be 19.15%.
Shares Statistics:
A total of 117.85M shares are outstanding, with a floating share count of 104.90M. Insiders hold about 12.00% of the company’s shares, while institutions hold 101.01% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 5.0 analysts. The consensus estimate for the next quarter is -$0.13, with high estimates of $0.0 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.2 and -$0.81 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is $0.34, with 6.0 analysts recommending between $1.25 and -$0.25.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $71.46M. It ranges from a high estimate of $74.2M to a low estimate of $67M. As of the current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $30.86MFor the next quarter, 5 analysts are estimating revenue of $79.36M. There is a high estimate of $87M for the next quarter, whereas the lowest estimate is $74M.
A total of 7 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $327.92M, while the lowest revenue estimate was $284.44M, resulting in an average revenue estimate of $305.12M. In the same quarter a year ago, actual revenue was $196.54MBased on 7 analysts’ estimates, the company’s revenue will be $429.97M in the next fiscal year. The high estimate is $540M and the low estimate is $339.9M.
